Metrics as of 10/15/2026, 06:20 PM (Berlin time), refresh in progress.
eXoZymes Stock
eXoZymes, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Michael Heltzen
- Employees
- 32
- Market cap
- $37 M
- IPO
- 13/11/2024
- Web
- exozymes.com
eXoZymes, Inc. operates as a development stage biotechnology company. It focuses on the development of enzyme modules and cell-free exozyme biosolutions for synthetic biology manufacturing. The company was formerly known as Invizyne Technologies, Inc. and changed its name to eXoZymes, Inc. in February 2025. eXoZymes,…
eXoZymes stock: price history
1D
-13.0%
1W
-24.1%
1M
-39.2%
6M
-61.9%
YTD
-63.3%
1Y
-68.7%
2Y
–
5Y
–
10Y
–
Next earnings date
Next earnings date
12/11/2026 (in 26 days)
Volatility around earnings
~16% stronger price swings than usual
Ask the agents about eXoZymes
eXoZymes stock metrics
P/E
-3.33
P/B
9.48
EV/EBITDA
-3.1
RETURN ON EQUITY
-78.8%
NET MARGIN
0.0%
DEBT/EQUITY
0.3
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
26.7%
FLOAT SHARES
2,475,357
AVG. DAILY VOLUME (30D)
8,800
Insider transactions (SEC)
Heltzen Michael
Heltzen Michael
Heltzen Michael
Heltzen Michael
Heltzen Michael
Institutional holders
Comparable stocks
Frequently asked questions about eXoZymes stock
What does eXoZymes do?
eXoZymes, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Michael Heltzen, the company employs around 32 people.
The IPO was on 13/11/2024; the stock trades on NASDAQ under the ticker EXOZ.
When does eXoZymes report next?
The next earnings date is 12/11/2026.
Around past earnings, price swings were roughly 16% stronger than usual.
Does eXoZymes pay a dividend?
No, eXoZymes currently does not pay a dividend.
Which stocks are comparable to eXoZymes?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get eXoZymes stock analyzed?
Clicking "Analyze stock" lets five strategies assess eXoZymes against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.